Skip to main content

Arixtra 10 mg/dose Disease Interactions

There are 5 disease interactions with Arixtra 10 mg/dose (fondaparinux).

Major

Factor Xa inhibitors (applies to Arixtra 10 mg/dose) bleeding

Major Potential Hazard, Moderate plausibility.

The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding as these agents increase the risk of bleeding and can cause serious or fatal hemorrhages. Caution is recommended when prescribing factor Xa inhibitors to patients at increased risk of bleeding, including patients undergoing procedures where bleeding may cause serious complications. Such patients include those undergoing spinal/epidural anesthesia or spinal puncture; these patients are at high risk of an epidural or spinal hematoma, which can result in long-term or permanent paralysis. In general, when using factor Xa inhibitors, the risk of thrombotic events should be weighed against the risk of bleeding.

References

  1. "Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals SUPPL-39 (2022):
  2. "Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC SUPPL-43 (2020):
  3. "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb SUPPL-34 (2021):
  4. "Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc. SUPPL-17 (2021):
View all 4 references
Major

Fondaparinux (applies to Arixtra 10 mg/dose) bacterial endocarditis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Endocarditis

The manufacturers state that bacterial endocarditis is a contraindication for the use of fondaparinux injection.

References

  1. "Product Information. Arixtra (fondaparinux)." Organon (2002):
Major

Fondaparinux (applies to Arixtra 10 mg/dose) renal disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The use of fondaparinux is contraindicated in patients with severe renal dysfunction (CrCl less than 30 mL/min). Fondaparinux increases the risk of bleeding in patients with renal dysfunction due to reduced clearance. This drug may cause prolonged anticoagulation in patients with CrCl 30 to 50 mL/min. Renal function should be assessed periodically during therapy, and fondaparinux should be discontinued immediately in patients who develop severe renal dysfunction while on treatment. After discontinuation of fondaparinux, its anticoagulant effects may persist for 2 to 4 days in patients with normal renal function and even longer in patients with renal dysfunction.

References

  1. "Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC SUPPL-43 (2020):
Moderate

Fondaparinux (applies to Arixtra 10 mg/dose) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Patients with liver dysfunction may be vulnerable to bleeding during fondaparinux therapy; these patients should be observed closely for signs/symptoms of bleeding. No dose adjustment is recommended in patients with mild to moderate liver dysfunction. No pharmacokinetic data are available for patients with severe liver dysfunction; fondaparinux should be used cautiously in these patients.

References

  1. "Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC SUPPL-43 (2020):
Moderate

Fondaparinux (applies to Arixtra 10 mg/dose) thrombocytopenia

Moderate Potential Hazard, Moderate plausibility.

Thrombocytopenia can occur with the administration of fondaparinux. Caution should be used when administered to patients with preexisting thrombocytopenia. Thrombocytopenia of any degree should be monitored closely and treatment should be discontinued if the platelet count falls below 100,000/mm3.

References

  1. "Product Information. Arixtra (fondaparinux)." Organon (2002):

Arixtra 10 mg/dose drug interactions

There are 166 drug interactions with Arixtra 10 mg/dose (fondaparinux).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.